Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IbrutiNib in SARS CoV-2 Induced Pulmonary Injury and Respiratory Failure (iNSPIRE)

NCT04375397 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04375397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04375397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IbrutiNib in SARS CoV-2 Induced Pulmonary Injury and Respiratory Failure (iNSPIRE)
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
June 6, 2020
Completion date
June 8, 2021
Enrollment
46 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus induced disease-2019 (covid-19)